Targeted patient recruitment can increase the likelihood of trial success and help cultivate use of precision medicine.

Harbour BioMed and Bristol Myers Squibb (BMS) have signed a multi-year, worldwide strategic partnership and licence agreement ...

INCOG BioPharma Services has announced an injectable drug manufacturing expansion at its Fishers facility in Indiana, US.

GSK's Exdensur (depemokimab) is now the first FDA-approved, twice-yearly add-on maintenance therapy for severe eosinophilic asthma.

Cellular Origins is a UK‑based company enabling scalable, factory‑led automation for cell and gene therapy manufacturing, and ...

Sanofi has agreed $1.7bn and $1.04bn licensing deals with Dren Bio and ADEL, respectively. Following the disappointment of a ...

BostonGene has won four awards in the Research & Development, Product Launches, and Innovation categories in the 2025 ...

Large deals in H2 2025 included Novartis’ $12 billion acquisition of Avidity Biosciences and Genmab’s buyout of Merus, ...

Amid profit forecast reductions, Pfizer is implementing a $7.7bn cost-cutting strategy, while investing into its ...

US-based private investment company SK Capital Partners’ affiliate is to invest in Swixx BioPharma to support its growth and ...

Akeega’s is now FDA indicated for mCSPC and mCRPC, widening the drug’s future market potential across the prostate cancer ...

With a lack of radiologists around the world, targeted uses of AI in Scotland are creating efficiencies in medical imaging.